Hasan, A
Wobrock, T
Guse, B
Langguth, B
Landgrebe, M
Eichhammer, P
Frank, E
Cordes, J
Wölwer, W
Musso, F
Winterer, G
Gaebel, W
Hajak, G
Ohmann, C
Verde, P E
Rietschel, M
Ahmed, R
Honer, W G
Dechent, P
Malchow, B
Castro, M F U
Dwyer, D
Cabral, C
Kreuzer, P M
Poeppl, T B
Schneider-Axmann, T
Falkai, P
Koutsouleris, N
Article History
Received: 9 March 2016
Revised: 6 July 2016
Accepted: 4 August 2016
First Online: 11 October 2016
Competing interests
: AH has been invited to scientific meetings by Lundbeck, Janssen-Cilag and Pfizer, and he received a paid speakership from Desitin, Otsuka and Lundbeck. He was member of a advisory board of Roche. TW has received paid speakerships from Alpine Biomed, AstraZeneca, Bristol–Myers–Squibb, Eli Lilly, I3G, Janssen-Cilag, Novartis, Lundbeck, Roche, Sanofi-Aventis, Otsuka and Pfizer, and has accepted travel or hospitality not related to a speaking engagement from AstraZeneca, Bristol–Myers–Squibb, Eli Lilly, Janssen-Cilag and Sanofi-Synthelabo, and has received restricted research grants from AstraZeneca, Cerbomed, I3G and AOK (health insurance company). JC was a member of an advisory board of Roche, accepted travel or hospitality not related to a speaking engagement from Servier, support for symposia from Inomed, Localite, Magventure, Roche, Mag & More, NeuroConn, Syneika, FBI Medizintechnik, Spitzer Arzneimittel and Diamedic. WW has received paid speakerships from Bristol–Myers–Squibb, Essex Pharma, Janssen-Cilag, Lilly Deutschland and Pfizer Neuroscience. He is a member of the Neuroscience Academy of Roche Pharma. WG has received symposia support from Janssen-Cilag GmbH, Neuss, Lilly Deutschland GmbH, Bad Homburg and Servier, Munich. He is a member of the Faculty of the Lundbeck International Neuroscience Foundation (LINF), Denmark. BL received honoraria and speakers’ fees from ANM, AstraZeneca, Autifony, Lundbeck, Merz, Magventure, Novartis, Pfizer and Servier, research funding from the Tinnitus Research Initiative, the German Research Foundation, the German Bundesministerium für Bildung und Forschung, the American Tinnitus Association, AstraZeneca and Cerbomed, funding for equipment from Magventure and Deymed and travel and accommodation payments from Lilly, Lundbeck, Servier and Pfizer. GH has received payments as speaker, consultant, author or for research funding during the last 5 years from Actelion, Affectis, AstraZeneca, Bayerische Motorenwerke, Bundesministerium für Bildung und Forschung, Bundesministerium für Strahlenschutz, Bristol-Meyers Squibb, Cephalon, Daimler Benz, Deutsche Forschungsgesellschaft, Elsevier, EuMeCom, Essex, Georg Thieme, Gerson Lerman Group Council of Healthcare Advisors, GlaxoSmithKline, Janssen-Cilag, Lilly, Lundbeck, Meda, Merck, Merz, Novartis, Pfizer, Proctor & Gamble, Sanofi-Aventis, Schering-Plough, Sepracor, Servier, Springer, Urban & Fischer and Volkswagen. WGH is an unpaid member of the Advisory Board of In Silico Biosciences, and a paid consultant to Otsuka/Lundbeck, Roche, Novartis, Eli Lilly, MDH Consulting and the Canadian Agency on Drugs and Technology in Health. PF was honorary speaker for Janssen-Cilag, AstraZeneca, Eli Lilly, Bristol–Myers–Squibb, Lundbeck, Pfizer, Bayer Vital, SmithKline Beecham, Wyeth and Essex. During the last 5 years, but not presently, he was a member of the advisory boards of Janssen-Cilag, AstraZeneca, Eli Lilly and Lundbeck. NK received paid speakership from Otsuka. The remaining authors declare no conflict of interest.